Grace Therapeutics
GRCE
7 hedge funds and large institutions have $479K invested in Grace Therapeutics in 2018 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 6 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.05% less ownership
Funds ownership: 0.07% → 0.02% (-0.05%)
45% less capital invested
Capital invested by funds: $879K → $479K (-$400K)
46% less funds holding
Funds holding: 13 → 7 (-6)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$24.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$527K |
| 2 |
PA
Perceptive Advisors
New York
|
-$117K |
| 3 |
VF
Virtu Financial
New York
|
-$23K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$19K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Bank of Montreal
Toronto,
Ontario, Canada
| $199K | – | – | – |
|
|
IIM
2
Intact Investment Management
Montreal,
Quebec, Canada
| $81K | – | – | – |
|
|
3
Renaissance Technologies
New York
| $79K | +$24.6K | +887 | +229% |
|
|
FDCDDQ
4
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $63K | – | – | – |
|
5
Morgan Stanley
New York
| $52K | – | – | – |
|
6
Royal Bank of Canada
Toronto,
Ontario, Canada
| $5K | -$805 | -29 | -25% |
|
|
RE
7
RBC Europe
London,
United Kingdom
| $39 | – | – | – |
|
|
AFM
8
Anson Funds Management
Dallas,
Texas
| – | -$527K | -14,263 | Closed |
|
|
PA
9
Perceptive Advisors
New York
| – | -$117K | -4,306 | Closed |
|
|
VF
10
Virtu Financial
New York
| – | -$23K | -856 | Closed |
|
|
11
Citadel Advisors
Miami,
Florida
| – | -$19K | -680 | Closed |
|
|
12
UBS Group
Zurich,
Switzerland
| – | -$3K | -94 | Closed |
|
GRCE Hedge Fund Activity: Q3 2018 in Review
7 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q3 2018, worth a combined $479K — down 45% from $879K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of GRCE and 0 opened new positions — a net loss of 6 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was Renaissance Technologies, adding an estimated $24.6K. The largest seller was Anson Funds Management, exiting entirely with an estimated $527K sold.
- 7 institutional investors held Grace Therapeutics (GRCE) as of Q3 2018, down from 13 in Q2 2018.
- Funds reported $479K of Grace Therapeutics stock for Q3 2018, down 45% quarter-over-quarter.
- 0 funds opened new Grace Therapeutics positions in Q3 2018 and 6 closed out, a net change of -6 holders.
- The largest Grace Therapeutics buyer in Q3 2018 was Renaissance Technologies, an estimated $24.6K added.
- The largest Grace Therapeutics seller in Q3 2018 was Anson Funds Management, an estimated $527K sold.
Based on aggregated 13F filings for Q3 2018.